A synthetic analog of parathyroid hormone-related protein (PTHrP) approved as an anabolic (bone-building) therapy for severe osteoporosis.

A synthetic somatostatin analog that has been a workhorse of endocrine and oncology practice since the 1980s.

A peptide-receptor radionuclide therapy (PRRT) — somatostatin analog conjugated to a beta-emitting radionuclide. Marketed as Lutathera. FDA-approved 2018 based on the Phase 3 NETTER-1 trial…

One of the oldest synthetic peptide therapies in continuous medical use — synthesized in 1953 by du Vigneaud (Nobel Prize that year), and on every…

A synthetic GnRH agonist administered as an intranasal spray — same paradoxical-suppression mechanism as leuprolide, different delivery route.

A synthetic GnRH agonist that paradoxically suppresses gonadal hormone production through receptor downregulation.

A 54-amino-acid peptide hormone (and its bioactive 10-amino-acid fragment kisspeptin-10) that sits at the apex of the reproductive endocrine axis — upstream of GnRH, regulating…

Teriparatide is the N-terminal 1-34 amino acid fragment of human parathyroid hormone (PTH). It is a synthetic, recombinant anabolic agent that represents the biologically active…

Nesiritide is the recombinant form of human B-type natriuretic peptide (BNP), a 32-amino acid peptide hormone. It is produced by the ventricular myocardium in response…

A second-generation somatostatin analog with broader receptor binding than octreotide or lanreotide — adds high affinity for SSTR1, SSTR2, SSTR3, and SSTR5.